Wednesday, July 8, 2026

pharma · Advanced Solid Tumors · Solid Tumor · PYXS

Pyxis Oncology

Pyxis Oncology patent portfolio — 3 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Boston, USA HQ
2019 Founded
71 Employees
Public company Type
PYXS · NYSE Ticker
Company details
Status
Public
HQ
Boston, USA
Founded
2019
Employees
71
Programs
8
Drugs
6
Patents
3
Intelligence · Patents

Pyxis Oncology patents

3 pharmaceutical patents indexed for Pyxis Oncology. 0 expire within 24 months.

Pyxis Oncology has 3 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. US 10675324

    Compositions and methods for modulating AT2R activity

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 10105411

    Compositions and methods for modulating AT2R activity

    Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 9700686

    Fluid delivery devices and methods

    Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Pyxis Oncology have?

3 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Pyxis Oncology patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.